[{"orgOrder":0,"company":"Imugene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imugene Gets FDA IND Approval for Phase-1 Trial of PD1-Vaxx","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Imugene"},{"orgOrder":0,"company":"Imugene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imugene Completes Enrolment of First Cohort of Patients in Phase I Clinical Trial of Checkpoint Immunotherapy Candidate PD1-VAXX","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Imugene"},{"orgOrder":0,"company":"Imugene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imugene Commences Cohort 2 Dosing in Phase 1 PD1-VAXX Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Imugene"},{"orgOrder":0,"company":"Imugene","sponsor":"City of Hope","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imugene And City Of Hope Announce First Patient Dosed In Phase 1 Trial To Test Cancer-Killing Oncolytic Virus Against Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Imugene"},{"orgOrder":0,"company":"Noxopharm","sponsor":"GenesisCare","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Noxopharm Alliance With GenesisCare","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Noxopharm"},{"orgOrder":0,"company":"Noxopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Noxopharm Reports Veyonda\u2019s Potential in Late-Stage Cancer at ASCO 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Noxopharm"},{"orgOrder":0,"company":"Noxopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orphan Drug Designation Granted to Noxopharm by US FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Noxopharm"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Grants Rare Pediatric Disease Designation (RPDD) to Paxalisib for DIPG","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Kazia Therapeutics"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Awards Orphan Drug Designation (ODD) To Paxalisib For Malignant Glioma, Including DIPG","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Kazia Therapeutics"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Oasmia Pharmaceutical","pharmaFlowCategory":"D","amount":"$46.0 million","upfrontCash":"$4.0 million","newsHeadline":"Kazia Licenses Cantrixil, a Clinical-Stage, First-in-Class Ovarian Cancer Drug Candidate, to Oasmia Pharmacetical AB","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Kazia Therapeutics"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Evotec","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kazia Enrols First Patient to EVT801 Phase I Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Kazia Therapeutics"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kazia Therapeutics Reports Promising Interim Data From Combination Study of Paxalisib With Radiotherapy in Treatment of Brain Metastases","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Kazia Therapeutics"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compelling Preclinical Data For Kazia's EVT801 Published In Peer-Reviewed Cancer Research Journal","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Kazia Therapeutics"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Evotec","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kazia Therapeutics (KZIA): EVT801 Data Published in Peer-Reviewed Journal","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Kazia Therapeutics"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kazia's Paxalisib Receives Fast Track Designation from FDA for Treatment of Solid Tumor Brain Metastases Harboring PI3K Pathway Mutations in Combination with Radiation Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Kazia Therapeutics"},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep\u2019s Partner, EOC Pharma, Reports Completion of Recruitment of Phase I Study of Efti","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Immutep"},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Completes Enrollment for the INSIGHT-004 Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Immutep"},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Reports Improving Results from INSIGHT-004 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Immutep"},{"orgOrder":0,"company":"Immutep","sponsor":"Eoc Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep\u2019s Chinese Partner, EOC Pharma, Expands Efti Trial Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Immutep"},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Reports Good Safety from First Five Patients in Triple Combination Therapy Efti Study, Insight-003","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Immutep"},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Granted New Patents in Japan and South Korea for First-in-Class LAG-3 Candidate, Eftilagimod Alpha in Chemo-Immunotherapy Combination","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Immutep"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immutep Announces Expansion of Triple Combination Therapy in 1st Line Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Immutep"},{"orgOrder":0,"company":"Immutep","sponsor":"Merck Group","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO\u00ae in Metastatic Urothelial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Large molecule","graph2":"Immutep"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in CUPID Study of Telix\u2019s Targeted Alpha Therapy Candidate for Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Telix Pharmaceuticals"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"ATONCO","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in Study of Targeted Alpha Therapy Candidate for Bladder Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Telix Pharmaceuticals"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in IPAX-2 Study of TLX101 Brain Cancer Therapy Candidate in Patients with Newly Diagnosed Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Telix Pharmaceuticals"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProstACT SELECT Study of TLX591 Interim Readout: Positive Results Confirm Safety and Tolerability","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Telix Pharmaceuticals"},{"orgOrder":0,"company":"Chimeric Therapeutics","sponsor":"WuXi Advanced Therapies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Chimeric Enters Strategic Manufacturing Partnership With WuXi Advanced Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Chimeric Therapeutics"},{"orgOrder":0,"company":"Chimeric Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chimeric Announces Launch of New Phase 1B Glioblastoma Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Chimeric Therapeutics"},{"orgOrder":0,"company":"AdvanCell","sponsor":"Point Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"POINT Biopharma and AdvanCell to Collaborate in the Development of Lead-212-Labeled Radioligands","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"AdvanCell"},{"orgOrder":0,"company":"Radiopharm Theranostics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Radiopharm Theranostics Receives FDA Orphan Drug Designation for Trivehexin (RAD 301) in Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Peptide","graph2":"Radiopharm Theranostics"},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Propanc Biopharma Purchases Pharma Grade Raw Materials for PRP Manufacture in Preparation for Phase I First-In-Human Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Propanc Biopharma"},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Propanc Biopharma Undertaking PRP Manufacturing & Development for Human Use","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Propanc Biopharma"},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Propanc Biopharma Presents 100 Years of Clinical Evidence for \u201cNovel\u201d Enzyme Therapeutic Approach to Treat Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Propanc Biopharma"},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Propanc Biopharma\u2019s CEO Believes Lead Asset Could Unlock Value as PRP Advances to Phase I, First-In-Human Study in Advanced Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Propanc Biopharma"},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Propanc Biopharma Receives Notice of Allowance for Proenzyme Compositions to Treat Cancer from the European Patent Office","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Propanc Biopharma"},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Propanc Biopharma\u2019s CEO to Attend 43rd Meeting of the European Organization of Research & Treatment of Cancer (EORTC), Dec 15 - 17","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Propanc Biopharma"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Efti (eftilagimod alpha) a soluble LAG-3 protein and MHC Class II agonist is being evaluated in combination with Bavencio (avelumab) under phase 1 clinical trials forthe treatment of patients with metastatic urothelial carcinoma.
TLX591 (177Lu-DOTA-TLX591) is first-in-class radio-antibody drug conjugate (rADC) investigational therapy, which is investigated for the the treatment of prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer.
Lead Product(s):
Lutetium-177 Rosopatamab Tetraxetan
TLX101 (4-L-[131I] iodo-phenylalanine, or 131I-IPA) is one of Telix's lead therapeutic clinical programs and has been granted orphan drug designation in the United States and Europe for glioblastoma therapy.
Lead Product(s):
[131I]Iodo-phenylalanine,Temozolomide
GDC-0084 (paxalisib) is a brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer.
The collaboration aims on the development of a global 212Pb radioisotope and radioligand supply chain to specifically support the development and commercialization of 212Pb-labeled radioligands including, 212Pb-ADVC001, a best-in-class treatment for metastatic prostate cancer.
CHM 1101 (Chlorotoxin CAR T Cell Therapy) is a first-in-class CAR T therapy that has the potential to address the high unmet medical need of patients with recurrent or progressive glioblastoma.
RAD301 (68Ga-Trivehexin) is a proprietary peptide-based molecule that targets avf6-integrin, a cellular marker for tumor invasion and metastatic growth, the expression of which correlates with decreased survival in several carcinomas.
The agreement aims to expand the INSIGHT-003 trial evaluating the combination of IMP321 (eftilagimod alpha), a soluble LAG-3 protein and first-in-class MHC class II agonist, in conjunction with standard-of-care combination of anti-PD-1 therapy and chemotherapy in 1L NSCLC.
EVT801 is an inhibitor of vascular endothelial growth factor receptors (VEGFR), which play an important role in angiogenesis and lymphangiogenesis (processes that contribute to tumor growth and metastasis), making VEGFR a well-established therapeutic target.
EVT801, a small-molecule, is a selective inhibitor of vascular endothelial growth factor receptor 3 (VEGFR3). EVT801 was confirmed in preclinical studies to be a potent and selective inhibitor of VEGFR3, with activity in the low nanomolar range.